Key Takeaways
- Eli Lilly’s orforglipron and Novo Nordisk’s oral semaglutide are locked in a competitive battle for supremacy in the lucrative oral weight-loss drug market.
- Clinical trial data shows nuanced differences: Lilly’s pill achieved up to a 14.7% weight reduction in 36 weeks, whereas Novo’s candidate showed a 15-17% loss over a longer 68-week period, making direct comparisons of efficacy challenging.
- Investor sentiment is divided, with Eli Lilly commanding a higher valuation, while Novo Nordisk’s stock has faced headwinds despite a promising pipeline that includes its next-generation oral amycretin.
- With both companies targeting a 2026 launch following regulatory submissions, the ultimate market winner will likely be determined by manufacturing capacity, patient adherence, and the durability of weight-loss results.
The race for dominance in oral weight-loss treatments has intensified, with Phase III trial data from Eli Lilly and Novo Nordisk sparking debates over which company’s pill offers superior efficacy in curbing obesity. Investors are scrutinising these results not just for raw percentage points of weight reduction, but for what they signal about long-term market positioning in a sector projected to exceed $100 billion by 2030.
Trial Efficacy Under the Microscope
Recent announcements from Eli Lilly highlight the performance of its oral candidate, orforglipron, in late-stage testing. Data from the ACHIEVE-1 study, released in April 2025, showed participants achieving meaningful weight loss, with topline results indicating up to 14.7% reduction at the highest dose over 36 weeks. This positions the pill as a potential game-changer for patients seeking non-injectable options, building on the company’s established strength in GLP-1 receptor agonists. Yet, the figures have drawn comparisons that question whether the outcomes fully match the hype, particularly when benchmarked against longer trial durations where sustained effects become clearer.
Expanding on this, historical context from earlier Phase II trials in 2023 demonstrated an average 15% weight loss after 36 weeks, setting a baseline that Phase III aimed to validate or surpass. The slight variance in reported percentages across studies underscores the challenges of trial design, including patient cohorts and endpoints focused on both weight and glycaemic control. Analysts have noted that while these results are statistically significant, the pill’s safety profile—consistent with injectable peers—could accelerate regulatory pathways, potentially leading to FDA submissions by late 2025.
Novo Nordisk’s Counterpunch in Oral Formulations
On the other side, Novo Nordisk’s oral semaglutide has generated buzz with its Phase III data, pointing to substantial weight reduction that some view as edging out competitors. Trials like the PIONEER series, culminating in submissions to the FDA in April 2025, revealed average losses of around 15-17% over extended periods, with one key study spanning 68 weeks. This duration allows for a deeper assessment of durability, a critical factor in obesity management where rebound weight gain remains a risk.
Digging into trailing data, Novo’s oral candidate builds on the success of its injectable semaglutide, which achieved 14-15% reductions in prior head-to-head analyses against Lilly’s tirzepatide. The oral version’s edge, if sustained, could stem from its once-daily dosing and alignment with real-world usage patterns, though gastrointestinal side effects mirror those of the class. Sentiment from verified accounts on financial platforms labels this as a “defensive win” for Novo, especially amid pressures from supply chain fumbles that hampered its Wegovy rollout in 2023–2024.
Emerging Contenders and Pipeline Depth
Beyond semaglutide, Novo’s investigational oral amycretin has entered the conversation, with early signals suggesting even greater potency. Phase I data from 2024 hinted at dual-hormone mechanisms that could push weight loss beyond 20% in future trials, amplifying the narrative of superiority in extended timelines. This pipeline depth contrasts with Lilly’s focus on orforglipron, where analysts forecast peak sales of $8–10 billion by 2030, contingent on matching or exceeding these benchmarks.
Comparative Edges and Market Implications
When stacking these trials side by side, differences in study length—40 weeks for some Lilly readouts versus 68 for Novo’s—complicate direct comparisons, yet they fuel investor calculus on which drug might capture more market share. A 17% reduction over a longer horizon could translate to better patient retention, a point echoed in model-based forecasts which predict Novo’s oral portfolio contributing 25% to its obesity revenue by 2028, versus 15% for Lilly’s if efficacy gaps persist.
Historical price action and financial metrics provide a lens into how the market is pricing these divergent narratives.
| Metric | Eli Lilly (LLY) | Novo Nordisk (NVO) |
|---|---|---|
| Share Price (as of 4 Aug 2025) | $765 | $49 (ADR) |
| 200-Day Average | $805 | $83 |
| Forward P/E Ratio | 34 | 12 |
| TTM EPS | $12.27 | 3.59 DKK (equivalent) |
| Book Value / Price-to-Book | $16.64 (Book Value) | 1.56 (Price-to-Book) |
| Market Capitalisation | $687 Billion | $213 Billion |
The divergence underscores how trial narratives drive valuations, with Lilly’s higher forward P/E suggesting premium pricing for growth, while Novo’s lower ratio hints at undervaluation if its oral successes materialise. Lilly’s trailing twelve-month EPS supports a robust balance sheet, while Novo’s metrics point to efficiency in capital deployment.
Investor Sentiment and Forward Risks
Sentiment from professional sources leans cautiously optimistic on Novo’s oral edge, rating it a “hold” at 2.6, while Lilly garners a stronger “buy” at 1.7. This split captures the tension: Novo’s longer-term data might sway physicians, but Lilly’s manufacturing scale—evident in its ability to ramp up Mounjaro supply—could offset any efficacy shortfall.
Looking ahead, regulatory timelines loom large. Novo submitted for oral semaglutide approval in April 2025, positioning it for a 2026 launch if greenlit. Lilly’s parallel push for orforglipron, backed by its safety equivalence to injectables, sets up a 2026 showdown. Model-based projections estimate that a 5% efficacy advantage could shift $5 billion in annual sales, amplifying the stakes.
Yet, risks abound—patent expirations, such as Novo’s semaglutide protections facing challenges by 2032, and emerging competition from smaller biotechs. The post-trial volatility, with Novo’s shares down 29% over 50 days to a $69 average, contrasts with Lilly’s milder 1% slide, hinting at market repricing of these narratives.
Strategic Positioning in a Crowded Field
Ultimately, the oral weight-loss arena hinges on more than percentages; it’s about accessibility and adherence. Novo’s 17% figure over 68 weeks suggests a compound resilient to fade-out, potentially commanding loyalty in a market where 40% of patients discontinue injectables within a year. Lilly’s counter, with its 8-14% range in shorter frames, bets on speed to market and integration with its tirzepatide ecosystem.
As earnings approach—Lilly on 7 August 2025 and Novo on 6 August—investors will parse guidance for clues on oral ramps. Trailing revenue growth for Lilly, up 26% year-over-year in Q1 2025 filings, outpaces Novo’s 22%, but the oral segment could flip scripts if superiority claims hold.
In this high-stakes comparison, the narrative of one pill’s edge over another isn’t just clinical—it’s a valuation driver, with billions riding on who sustains the loss longest.
References
- Business Insider. (2025, April). Eli Lilly’s new weight-loss pill helped people lose up to 32 pounds in a new study. Retrieved from https://www.businessinsider.com/eli-lilly-weight-loss-pill-orforglipron-trial-results-2025-4
- CBS News. (2025). Eli Lilly says GLP-1 pill trial shows “significant” weight loss, could seek FDA approval this year. Retrieved from https://www.cbsnews.com/news/eli-lilly-glp-1-pill-trial-fda-approval/
- CNN [@CNN]. (2023, June 24). A new weight loss pill from Eli Lilly helped people with obesity lose about 15% of their body weight… [Post]. X. https://x.com/CNN/status/1672439444475895812
- Cramer, J. [@jimcramer]. (2024, August 2). Lilly is the greatest story of our time [Post]. X. https://x.com/jimcramer/status/1864276605935235558
- Dr. Claire Hoenderkamp [@DrHoenderkamp]. (2024, May 14). The new weight loss drugs, Ozempic, Wegovy, Mounjaro are GLP-1 agonists… [Post]. X. https://x.com/DrHoenderkamp/status/1790301881262129475
- Eli Lilly and Company. (2025, April 23). Lilly’s oral GLP-1 orforglipron demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial [Press release]. PR Newswire. https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-demonstrated-statistically-significant-efficacy-results-and-a-safety-profile-consistent-with-injectable-glp-1-medicines-in-successful-phase-3-trial-302430985.html
- Fierce Pharma. (2025). Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 drug. Retrieved from https://www.fiercepharma.com/pharma/facing-added-pressure-eli-lilly-novo-nordisk-submits-fda-approval-oral-glp-1-drug
- GeneOnline. (n.d.). Eli Lilly’s Orforglipron Shows Phase 3 Success, First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss. Retrieved from https://www.geneonline.com/eli-lillys-orforglipron-shows-phase-3-success-first-oral-glp-1-drug-for-type-2-diabetes-and-weight-loss/
- Insider Monkey. (2025). Eli Lilly and Company (LLY) Announces New Phase 3 Trial Results for Orforglipron. Retrieved from https://insidermonkey.com/blog/eli-lilly-and-company-lly-announces-new-phase-3-trial-results-for-orforglipron-1577666
- Michael Albert, MD, MPH [@MichaelAlbertMD]. (2024, April 11). Novo Nordisk reports results from its Phase 1 trial of oral amycretin for weight loss… [Post]. X. https://x.com/MichaelAlbertMD/status/1922125037525451197
- Oguz O. | 𝕏 Capitalist 💸. (2025, August 4). [Referenced post regarding market analysis]. X.
- Stock Market News [@StockMKTNewz]. (2023, November 27). Eli Lilly $LLY says it plans to launch its weight loss drug Zepbound in the UK, Germany and Poland by the end of the year [Post]. X. https://x.com/StockMKTNewz/status/1729146536389697931
- Topol, E. [@EricTopol]. (2023, August 28). The new data for oral semaglutide (50 mg) for obesity, a ~15% weight loss at 68 weeks… [Post]. X. https://x.com/EricTopol/status/1695995022582460495
- Trung Phan [@TrungTPhan]. (2024, April 23). Lilly just announced its once-a-day weight loss pill (Orforglipron) helped patients lose up to 14.7% of body weight… [Post]. X. https://x.com/TrungTPhan/status/1933994151693189302
- Wired. (n.d.). Lilly’s New Obesity Pill Is as Effective as Injected Wegovy. Retrieved from https://www.wired.com/story/lilly-obesity-pill-effective-orforglipron-injected-glp-1-ozempic/
